Trial reportBritish medical journal (Clinical research ed.)1987
Cyclosporin treatment of IgA nephropathy: a short term controlled trial.
Trial report in British medical journal (Clinical research ed.), 1987. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 5 syntheses or guidelines pooled it, 72 citations in OpenAlex.
- Efficacy and safety of agents for IgA nephropathy: a network meta-analysis of randomized controlled trials.Frontiers in medicine · 2025Pooled it
- Immunosuppressive agents for treating IgA nephropathy.The Cochrane database of systematic reviews · 2020Pooled it
- Efficacy and safety of calcineurin inhibitor treatment for IgA nephropathy: a meta-analysis.BMC nephrology · 2017Pooled it
- The effect of calcineurin inhibitors in the treatment of IgA nephropathy: A systematic review and meta-analysis (PRISMA).Medicine · 2016Pooled it
- Effect of cyclosporine on blood pressure.The Cochrane database of systematic reviews · 2010Pooled it
- Cyclosporine A combined with medium/low dose prednisone in progressive IgA nephropathy.The Kaohsiung journal of medical sciences · 2014Trial
- Effects of cyclosporin A therapy combined with steroids and angiotensin converting enzyme inhibitors on childhood IgA nephropathy.Journal of Korean medical science · 2010Trial
- IgA Vasculitis (Henoch-Schönlein Purpura): An Update on Treatment.Journal of clinical medicine · 2024Review
- Navigating Adult-Onset IgA Vasculitis-Associated Nephritis.Life (Basel, Switzerland) · 2024Review
- Current treatment of IgA nephropathy.Seminars in immunopathology · 2021Review
- Efficacy and Safety of Immunosuppressive Monotherapy Agents for IgA Nephropathy: A Network Meta-Analysis.Frontiers in pharmacology · 2020Article
- Has The Time Arrived to Refine The Indications of Immunosuppressive Therapy and Prognosis in IgA Nephropathy?Journal of clinical medicine · 2019Review
- Why, when and how should immunosuppressive therapy considered in patients with immunoglobulin A nephropathy?Clinical and experimental immunology · 2016Review
- The Treatment of IgA Nephropathy.Kidney diseases (Basel, Switzerland) · 2015Review
- Nephrology, dialysis and transplantation.Postgraduate medical journal · 1993Review
- Autoimmunity and the pathogenesis of glomerulonephritis.Pediatric nephrology (Berlin, Germany) · 1990Review
- The effect of cyclosporin A on the interstitial mononuclear cell infiltration and the induction of Heymann's nephritis.Clinical and experimental immunology · 1990Article
- Treatment of severe IgA nephropathy in children.Pediatric nephrology (Berlin, Germany) · 1989Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cyclosporin's known regulatory effects on the immune system suggest that it may be useful in treating patients with IgA nephropathy. A randomised prospective single blind study of 19 patients with IgA nephropathy and proteinuria (greater than 1.5 g/day) was conducted to determine the therapeutic value of cyclosporin. The patients were divided into two groups: nine patients were given oral cyclosporin (5 mg/kg/day) for 12 weeks and 10 patients a placebo. The two groups were comparable in age of presentation, ratio of men to women, plasma creatinine and serum IgA concentrations, creatinine clearance, daily urinary protein excretion, severity of renal histopathological changes, and prevalence of hypertension. A significant reduction of proteinuria and an increase of plasma albumin concentration was observed with treatment with cyclosporin. Nevertheless, a significant rise of plasma creatinine concentration and a fall in creatinine clearance was found in patients after six weeks' treatment with cyclosporin, although the plasma cyclosporin concentrations were maintained within a narrow therapeutic range. Serum IgA concentrations were reduced in seven patients. Renal function improved within eight weeks after treatment was stopped. Three months after treatment was stopped proteinuria remained less than half of the pretreatment values in three patients. No similar biochemical changes were observed in the controls. Short term cyclosporin therapy may be beneficial in reducing proteinuria in some patients with IgA nephropathy. As transient renal impairment was seen, despite cyclosporin concentrations being maintained within a narrow therapeutic range, indiscriminate use of cyclosporin in glomerulonephritis should be discouraged.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.